FKBP5 polymorphisms and antidepressant response in geriatric depression.
Genetic variation at the FKBP5 locus has been reported to affect clinical outcomes in patients treated with antidepressant medications in several studies. However, other reports have not confirmed this association. FKBP5 may regulate the sensitivity of the hypothalamic-pituitary-adrenal axis. We tested two FKBP5 single nucleotide polymorphisms (rs1360780 and rs3800373) in a sample of 246 geriatric patients treated for 8 weeks in a double-blind randomized comparison trial of paroxetine and mirtazapine. These two polymorphisms had previously been reported to predict efficacy in depressed patients treated with selective serotonin reuptake inhibitors such as paroxetine, and those treated with mirtazapine, an agent with both serotonergic and noradrenergic actions. However, we found no significant associations between these FKBP5 genetic variants and clinical outcomes. Neither mean Hamilton Depression Rating Scale scores nor time to remission or response were predicted by FKBP5 genetic variation. These results suggest that FKBP5 is unlikely to play a major role in determining antidepressant treatment outcomes in geriatric patients.
Sarginson
Jane E
JE
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
Lazzeroni
Laura C
LC
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
Ryan
Heather S
HS
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
Schatzberg
Alan F
AF
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
Murphy
Greer M
GM
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy* / Q000235:genetics*; D004311:Double-Blind Method; D005260:Female; D014644:Genetic Variation; D005853:Geriatrics / Q000379:methods*; D006801:Humans; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078785:Mirtazapine; D017374:Paroxetine / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D017422:Sequence Analysis, DNA; D022021:Tacrolimus Binding Proteins / Q000235:genetics*; D016896:Treatment Outcome; D000099159:Tacrolimus Binding Protein 5
D000928:Antidepressive Agents; D008803:Mianserin; D000078785:Mirtazapine; D017374:Paroxetine; D022021:Tacrolimus Binding Proteins; D000099159:Tacrolimus Binding Protein 5
BMC Psychiatry. 2006 Nov 02;6:52
17081296
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Biol Psychiatry. 2006 Dec 15;60(12):1299-303
17014829
Psychiatry Res. 2007 Jul 30;152(1):37-44
17383015
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
6080235
Biol Psychiatry. 2008 Jun 15;63(12):1103-10
18191112
J Neuropathol Exp Neurol. 1997 Dec;56(12):1269-75
9413275
Psychoneuroendocrinology. 2009 Jan;34(1):99-109
18829172
Am J Geriatr Psychiatry. 2002 Sep-Oct;10(5):541-50
12213688
Nat Genet. 2004 Dec;36(12):1319-25
15565110
Br J Radiol. 2007 Dec;80 Spec No 2:S99-108
18445750
JAMA. 2008 Mar 19;299(11):1291-305
18349090
Ann N Y Acad Sci. 2008 Mar;1124:127-44
18400928
Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 5;144B(8):1097-8
17721930
Pharmacogenomics. 2008 Jul;9(7):841-6
18597649
J Affect Disord. 2007 Dec;104(1-3):83-90
17467808
Am J Psychiatry. 2003 Oct;160(10):1830-5
14514498
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1037-47
18326728
J Pathol. 2007 Jan;211(2):173-80
17200939
Drugs Aging. 2004;21(8):531-54
15182217